List of Excipients in Branded Drug VEVYE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Harrow Eye LLC	VEVYE	cyclosporine ophthalmic solution	82667-900	1,1,1,2,2,3,3,4,4-NONAFLUORONONANE
Harrow Eye LLC	VEVYE	cyclosporine ophthalmic solution	82667-900	ALCOHOL
Novaliq GmbH	VEVYE	cyclosporine ophthalmic solution	83339-002	1,1,1,2,2,3,3,4,4-NONAFLUORONONANE
Novaliq GmbH	VEVYE	cyclosporine ophthalmic solution	83339-002	ALCOHOL

VEVYE Excipient Strategy and Commercial Opportunities

Last updated: August 20, 2026

VEVYE is a differentiated dry-eye product built around a single nonaqueous excipient, perfluorobutylpentane, also known as F4H5. The excipient dissolves cyclosporine at 0.1% without water, surfactants, oils, or preservatives. This formulation strategy supports a preservative-free multidose presentation, avoids conventional aqueous emulsion architecture, and creates potential barriers in formulation know-how, raw-material qualification, device compatibility, and manufacturing scale-up.

VEVYE was approved by the U.S. Food and Drug Administration on May 18, 2023, for the treatment of signs and symptoms of dry eye disease. Harrow holds U.S. commercial rights, while Novaliq developed the EyeSol technology platform and VEVYE formulation.[1,2]

What excipient does VEVYE use?

VEVYE contains cyclosporine ophthalmic solution 0.1% and perfluorobutylpentane as its inactive ingredient.

Product attribute	VEVYE
Active ingredient	Cyclosporine
Strength	0.1%, equivalent to 1 mg/mL
Dosage form	Ophthalmic solution
Primary excipient	Perfluorobutylpentane, F4H5
Preservative	None
Water phase	None in the finished formulation
Administration	One drop in each eye twice daily
FDA status	Approved NDA product
Technology platform	Novaliq EyeSol
U.S. commercial company	Harrow

The formulation is materially different from conventional cyclosporine products. Restasis is an aqueous cyclosporine ophthalmic emulsion, while Cequa is a nanomicellar aqueous solution. VEVYE uses a semifluorinated alkane to solubilize cyclosporine in a water-free system.[1,3,4]

How does perfluorobutylpentane work in VEVYE?

Perfluorobutylpentane is a semifluorinated alkane designed to dissolve lipophilic compounds such as cyclosporine. The formulation is placed on the ocular surface, where the volatile component evaporates. This leaves cyclosporine available at the ocular surface without requiring a conventional oil-in-water emulsion or surfactant-based micelle system.

The excipient contributes several technical functions:

1. It acts as the delivery vehicle for cyclosporine.
2. It enables a water-free formulation.
3. It supports preservative-free multidose packaging.
4. It reduces dependence on emulsifiers and surfactants.
5. It may improve ocular tolerability relative to some preserved or surfactant-containing products.

The commercial value of F4H5 therefore exceeds its role as an inactive ingredient. It is part of the product’s delivery technology, regulatory differentiation, and potential intellectual-property position.

What formulation advantages does VEVYE’s excipient strategy create?

VEVYE’s formulation strategy has four principal advantages.

Preservative-free multidose delivery

The absence of water reduces the conditions that support microbial growth. This allows VEVYE to use a multidose bottle without a conventional preservative system. Preservative-free delivery is commercially relevant for chronic dry-eye treatment because repeated exposure to preservatives can affect ocular-surface tolerability.

The formulation does not eliminate the need for validated container-closure integrity, microbial limits, in-use stability, and dosing-performance testing. It shifts the quality burden from preservative efficacy toward packaging, fill-finish, and device controls.

Avoidance of conventional emulsion components

Restasis relies on an emulsion system. Such systems require control of droplet size, phase stability, surfactants, mixing conditions, and physical uniformity. VEVYE’s solution format reduces some of those manufacturing variables.

The change also creates a product-positioning advantage. VEVYE can be marketed as a cyclosporine solution rather than another cyclosporine emulsion.

Low-complexity composition

The finished formulation has a short ingredient list. A one-excipient system can simplify some analytical and supply-chain activities, provided the excipient is available at pharmaceutical quality and the container system is compatible.

A short ingredient list does not automatically create a low-risk product. Perfluorobutylpentane requires tight control of identity, purity, residual solvents, fluorinated impurities, volatility, fill volume, and container interaction.

Potential tolerability differentiation

VEVYE’s label includes ocular instillation-site pain as a reported adverse reaction, but the product’s preservative-free and water-free profile gives the commercial team a basis for positioning around ocular-surface tolerability. Claims must remain consistent with the approved label and comparative clinical evidence.

How does VEVYE compare with Restasis, Cequa, and Xiidra?

VEVYE competes in the prescription dry-eye market against cyclosporine and lifitegrast products.

Product	Active ingredient	Formulation approach	Preservative-free profile	Key excipient strategy
VEVYE	Cyclosporine 0.1%	Water-free ophthalmic solution	Yes	Perfluorobutylpentane
Restasis	Cyclosporine 0.05%	Aqueous emulsion	Yes, in current unit-dose presentation	Emulsion system
Cequa	Cyclosporine 0.09%	Nanomicellar solution	Yes	Nanomicellar delivery system
Xiidra	Lifitegrast 5%	Aqueous solution	Yes	Conventional aqueous formulation

VEVYE’s highest technical differentiation is against Restasis because both products contain cyclosporine but use materially different delivery systems. Against Cequa, the differentiation is the nonaqueous semifluorinated-alkane vehicle rather than a nanomicellar system. Against Xiidra, VEVYE competes through mechanism, dosing experience, tolerability, and product handling rather than direct excipient similarity.

What commercial opportunities does VEVYE’s excipient create?

Licensing the EyeSol platform

The primary commercial opportunity is platform licensing. EyeSol can potentially support additional ophthalmic products involving poorly water-soluble active ingredients. Candidates could include anti-inflammatory agents, immunomodulators, corticosteroids, or other compounds requiring nonaqueous ocular delivery.

A platform deal could include:

• Upfront payments for formulation and technology access
• Development and regulatory milestones
• Product royalties
• Territory-specific commercialization rights
• Manufacturing or excipient-supply obligations
• Rights to follow-on formulations

The platform has greater strategic value if the excipient and delivery process can be reused across multiple active ingredients rather than remaining limited to VEVYE.

Follow-on dry-eye formulations

The same excipient strategy could support:

• Higher or lower cyclosporine strengths
• Once-daily dosing
• Combination products
• Postoperative ocular inflammation products
• Products for meibomian gland dysfunction
• Adjunctive therapies for severe ocular-surface disease

A follow-on product would need to establish clinical, pharmaceutical, or adherence value. A simple strength change may be vulnerable to substitution unless it creates a meaningful dosing or efficacy advantage.

Private-label and regional partnerships

Harrow’s U.S. commercial rights and Novaliq’s technology ownership create a basis for regional partnerships. Potential counterparties include ophthalmology companies with sales forces in Europe, Asia, Latin America, and the Middle East.

The strongest regional opportunity is likely where:

• Preservative-free products command a premium
• Dry-eye diagnosis and prescription treatment are expanding
• Local competitors rely on preserved aqueous drops
• Ophthalmologists value multidose convenience
• Regulatory agencies accept an established foreign clinical and manufacturing package

Excipient supply and dual sourcing

Perfluorobutylpentane is a potential strategic bottleneck. A supplier able to produce pharmaceutical-grade material with consistent purity, low particulate burden, controlled volatility, and validated packaging could obtain substantial bargaining power.

Commercial opportunities exist in:

• Qualified secondary manufacturing
• Regional excipient supply
• Analytical reference standards
• Stability and compatibility testing
• Specialized ophthalmic fill-finish
• Device and bottle systems compatible with volatile solvents

Dual sourcing may be difficult if the excipient is closely tied to proprietary specifications or a single manufacturing process. That difficulty can strengthen the incumbent product’s operational moat while increasing supply-continuity risk.

What manufacturing barriers protect VEVYE?

The principal manufacturing barriers are process-specific rather than ingredient-count barriers.

Excipient control

The manufacturer must control:

• Chemical identity and composition
• Fluorinated impurity profile
• Water content
• Residual volatile materials
• Particulates
• Batch-to-batch solubility performance
• Storage and transport conditions

Because the excipient is volatile and chemically distinct from typical ophthalmic vehicles, standard aqueous-product controls may not be sufficient.

Drug-excipient compatibility

The product requires evidence that cyclosporine remains chemically and physically stable in perfluorobutylpentane through shelf life and in-use conditions. Compatibility must also be demonstrated with the bottle, closure, tip, label, and secondary packaging.

Potential failure modes include:

• Solvent loss
• Container permeation
• Extractables and leachables
• Changes in delivered volume
• Cyclosporine precipitation
• Tip wetting or clogging
• Inconsistent drop formation

Fill-finish capability

A nonaqueous volatile ophthalmic product may require specialized filling, environmental controls, and container-closure qualification. These requirements can limit the number of contract manufacturers capable of producing an equivalent product at commercial scale.

The fill-finish process is therefore a potential barrier to rapid generic replication, even if a competitor can identify the active ingredient and excipient.

What patents protect VEVYE’s formulation and delivery technology?

VEVYE’s protection is expected to rely on a combination of formulation patents, delivery-platform patents, manufacturing know-how, regulatory exclusivity, trademarks, and trade secrets.

The most valuable claim categories are likely to include:

• Cyclosporine dissolved in a semifluorinated alkane
• Specific concentrations and dosing regimens
• Water-free ophthalmic compositions
• Preservative-free multidose systems
• Container-closure configurations
• Methods of treating dry-eye disease
• Manufacturing and filling processes
• Stability and impurity-control methods

The excipient itself may be difficult to protect broadly if it is an established chemical entity. The stronger strategy is usually to claim the composition, concentration, treatment method, device, and process in combination.

Patent scope should be evaluated claim by claim. A patent covering “cyclosporine in perfluorobutylpentane” may create a meaningful formulation barrier, while a narrow claim limited to a concentration or dosing schedule may provide less protection against design-around products.

What is the FDA and Orange Book status of VEVYE?

VEVYE is an FDA-approved prescription ophthalmic product marketed under an NDA. The FDA-approved label identifies cyclosporine ophthalmic solution 0.1% and perfluorobutylpentane as the inactive ingredient.[1]

Because cyclosporine is an established active ingredient, VEVYE should not be analyzed as a conventional new chemical entity. The relevant exclusivity and patent questions are:

• Whether FDA granted approval-based exclusivity for new clinical investigations
• Whether patents are listed in the Orange Book
• Which claims cover the drug product or approved method of use
• Whether a future ANDA applicant could submit a Paragraph IV certification
• Whether the listed claims would block approval, launch, or only create litigation exposure

A generic applicant seeking approval before relevant listed patent expiration could file a Paragraph IV certification. The NDA holder would then have the option to bring infringement litigation within the statutory period, potentially triggering a 30-month stay of approval under the Hatch-Waxman framework.[5]

The key competitive issue is whether a generic can reproduce the required ophthalmic performance while avoiding formulation and method-of-use claims. For VEVYE, the excipient and container system may be as important as the active ingredient in that analysis.

When does VEVYE lose exclusivity?

VEVYE’s commercial exclusivity has several separate components.

Protection category	Relevance to VEVYE
New chemical entity exclusivity	Unlikely to apply because cyclosporine is an established active ingredient
New clinical investigation exclusivity	Potentially relevant if FDA granted it for qualifying studies
Orange Book patents	Potentially relevant to ANDA approval and Paragraph IV litigation
Formulation patents	May protect cyclosporine and perfluorobutylpentane combinations
Method-of-use patents	May protect treatment regimens or patient populations
Trade secrets	May protect excipient specifications, process parameters, and device controls
Trademark protection	Protects the VEVYE brand, not the active formulation

Patent expiry, rather than the product’s approval anniversary, is likely to determine the practical generic-entry date. A competitor may also enter through a non-infringing formulation, a 505(b)(2) application, or a licensed product pathway rather than a direct ANDA.

What generic entry risks exist for VEVYE?

VEVYE faces three principal entry scenarios.

Direct ANDA challenge

A generic applicant could seek to match the active ingredient, concentration, route, dosage form, and performance characteristics. The applicant would need to address the listed formulation and method-of-use patents through certifications.

This route is commercially attractive if the reference product’s formulation can be characterized without replicating protected manufacturing know-how.

505(b)(2) product

A 505(b)(2) applicant could develop a different cyclosporine ophthalmic formulation and rely partly on VEVYE or other FDA findings. A nonaqueous or alternative-solvent product could avoid some formulation claims while competing for the same prescriptions.

Therapeutic substitution

Restasis, Cequa, Xiidra, lifitegrast products, compounded cyclosporine, and future dry-eye therapies can erode VEVYE demand without directly challenging its patents.

The product’s defensibility is strongest where physicians value its specific delivery system and weakest where payers treat cyclosporine products as interchangeable.

How strong is VEVYE’s patent estate?

VEVYE’s potential patent strength is moderate to high for formulation-specific replication and lower for broad cyclosporine exclusivity.

Estate component	Indicative strength
Cyclosporine active ingredient	Low, because it is long established
Perfluorobutylpentane vehicle	Moderate, depending on claim breadth
Specific cyclosporine-F4H5 composition	High if claims are broad and valid
Preservative-free multidose system	Moderate
Treatment methods	Variable and vulnerable to carve-outs
Manufacturing process	High as a trade-secret barrier, but weaker as a patent-only barrier
Brand and commercial positioning	Strong against substitution, not against generic entry

The most defensible assets are likely the combination of excipient, active ingredient, concentration, container system, and manufacturing controls. A competitor may be able to avoid one claim category but still face cumulative development and regulatory costs.

Which companies are competing with VEVYE?

The competitive field includes AbbVie through Restasis, Sun Pharmaceutical Industries through Cequa, Bausch + Lomb and other companies marketing cyclosporine products, and Novartis through Xiidra-related commercial channels and legacy rights structures.

Competition occurs across four dimensions:

• Active ingredient and mechanism
• Formulation tolerability
• Dosing frequency
• Payer and pharmacy access

VEVYE’s excipient strategy supports premium positioning, but formulary access and physician familiarity remain central to market share. The product must justify its price against lower-cost cyclosporine alternatives and established lifitegrast products.

What revenue exposure is linked to the VEVYE excipient strategy?

The excipient strategy affects revenue through price, persistence, switching, and supply continuity.

A differentiated vehicle can support:

• Premium pricing
• Better adherence through convenient multidose packaging
• Reduced preservative-related switching
• Expansion into severe or treatment-resistant dry-eye patients
• Licensing revenue from additional EyeSol products

The main commercial risks are:

• Limited reimbursement
• Physician reluctance to switch stable patients
• Manufacturing capacity constraints
• Excipient supply concentration
• A competing nonaqueous or preservative-free product
• Generic or 505(b)(2) entry after patent expiry

Publicly disclosed revenue should be separated from total ophthalmology revenue and from sales of other Harrow products. VEVYE-specific revenue, prescription growth, gross margin, and commercial investment are the appropriate metrics for assessing the economic value of the excipient platform.

Key Takeaways

• VEVYE uses perfluorobutylpentane, or F4H5, as its principal excipient.
• The product is a preservative-free, water-free cyclosporine ophthalmic solution.
• The excipient is part of the delivery technology, not merely an inactive formulation component.
• The strongest protection is likely to come from combination claims covering cyclosporine, F4H5, concentration, device, and manufacturing process.
• The formulation may create meaningful generic barriers through excipient qualification, container compatibility, fill-finish requirements, and performance testing.
• EyeSol has potential value beyond VEVYE through licensing and follow-on ophthalmic products.
• VEVYE competes with Restasis, Cequa, Xiidra, and future cyclosporine or dry-eye formulations.
• Generic-entry exposure will depend on Orange Book listings, patent claim scope, FDA exclusivity, and the feasibility of a 505(b)(2) alternative.
• The principal commercial risks are payer substitution, supply concentration, and competing preservative-free delivery systems.

FAQs

Is perfluorobutylpentane a conventional ophthalmic excipient?

No. It is a specialized semifluorinated alkane used as the vehicle in VEVYE’s water-free ophthalmic solution.

Does VEVYE contain benzalkonium chloride?

No. VEVYE is labeled as a preservative-free ophthalmic product.

Can VEVYE’s excipient be used in other drugs?

Potentially. The EyeSol platform may be applicable to other poorly water-soluble ophthalmic active ingredients, subject to formulation, safety, manufacturing, and regulatory requirements.

Is VEVYE an emulsion like Restasis?

No. VEVYE is labeled as a cyclosporine ophthalmic solution. Restasis uses an emulsion-based delivery system.

What is the main intellectual-property risk for a VEVYE competitor?

The primary risk is infringement of claims covering the cyclosporine and perfluorobutylpentane composition, the multidose preservative-free delivery system, or related manufacturing and treatment methods.

References

1. U.S. Food and Drug Administration. (2023). VEVYE (cyclosporine ophthalmic solution) 0.1% prescribing information. Harrow, Inc.

2. U.S. Food and Drug Administration. (2023). VEVYE approval letter and product information. Center for Drug Evaluation and Research.

3. Allergan, Inc. (2018). RESTASIS (cyclosporine ophthalmic emulsion) 0.05% prescribing information.

4. Sun Pharmaceutical Industries, Inc. (2018). CEQUA (cyclosporine ophthalmic solution) 0.09% prescribing information.

5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.